Ecstasy counteracts catalepsy in rats,
an anti-parkinsonian effect?

by
Schmidt W, Mayerhofer A, Meyer A, Kovar K.
Zoological Institute, Neuropharmacology,
Mohlstrasse 54/1, University Tubingen,
72074, Tubingen, Germany
Neurosci Lett 2002 Sep 27;330(3):251


ABSTRACT

Parkinson's disease is due to a dopamine deficiency caused by the degeneration of midbrain dopamine neurons. Current therapies are aimed to substitute dopamine or to directly stimulate postsynaptic dopamine receptors. However, not all patients profit from current therapies to the same extent, even serious side effects such as dyskinesias are complicating the therapy. Therefore, there is still a need for better anti-parkinsonian drugs. Here we show that some compounds from the 'Ecstasy'-derivatives exert potent anti-parkinsonian activity. 3,4-Methylenedioxymethamphetamine, 'Ecstasy' dose-dependently and very potently reversed haloperidol-induced parkinsonism in the rat. From the supraadditive effect of the enantiomers it may be concluded that both enantiomers contribute to the antiparkinsonian effects at two different target sites.

Dr Ricaurte
Controversies
Oxidative stress
Locomotor effects
MDMA v fenfluramine
Cutaneous vasoconstriction
Ecstasy/MDMA and cannabis
Arginine-vasopressin release
Phosphatidylinositol turnover
MDMA, loud noise and the heart
Ecstasy, serotonin, and dopamine
MDMA, HIV and antiretroviral agents
Serotonin, noradrenline and dopamine
MDMA/polydrug users in the UK and Italy